Browsing by Author "Maity, Pritam"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Naturally occurring fused pyrimidine derivatives and their medicinal attributes
    (Elsevier, 2022-10-14T00:00:00) Maity, Pritam; Katiyar, Madhurendra K.; Kumar, Raj
    A wide variety of fused pyrimidine derivatives, mainly occurring as alkaloids, are obtained from different natural sources worldwide. These have been documented to exert some important biological activities including anticancer, antimicrobial, anti-inflammatory, etc. Based on the natural source, these fused pyrimidine derivatives are categorized and discussed further in the subsequent sections highlighting their medicinal attributes. � 2023 Elsevier Ltd. All rights reserved.
  • No Thumbnail Available
    Item
    Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities
    (American Chemical Society, 2023-02-22T00:00:00) Maity, Pritam; Chatterjee, Joydeep; Patil, Kiran T.; Arora, Sahil; Katiyar, Madhurendra K.; Kumar, Manvendra; Samarbakhsh, Amirreza; Joshi, Gaurav; Bhutani, Priyadeep; Chugh, Manoj; Gavande, Navnath S.; Kumar, Raj
    Epidermal growth factor receptor (EGFR) is an oncogenic drug target and plays a critical role in several cellular functions including cancer cell growth, survival, proliferation, differentiation, and motility. Several small-molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) have been approved for targeting intracellular and extracellular domains of EGFR, respectively. However, cancer heterogeneity, mutations in the catalytic domain of EGFR, and persistent drug resistance limited their use. Different novel modalities are gaining a position in the limelight of anti-EGFR therapeutics to overcome such limitations. The current perspective reflects upon newer modalities, importantly the molecular degraders such as PROTACs, LYTACs, AUTECs, and ATTECs, etc., beginning with a snapshot of traditional and existing anti-EGFR therapies including small molecule inhibitors, mAbs, and antibody drug conjugates (ADCs). Further, a special emphasis has been made on the design, synthesis, successful applications, state-of-the-art, and emerging future opportunities of each discussed modality. � 2023 American Chemical Society.